Download PDF
Onkologische Welt 2017; 08(05): 228-230
DOI: 10.1055/s-0038-1639638
Fallbericht
Schattauer GmbH

Paraneoplastische erosive Arthritis, Rheumafaktorund Anti-CCP-positiv, bei B-Zell-Lymphom

M. Braun
1   HELIOS Seehospital Sahlenburg, Abt. Innere Medizin/Rheumatologie, Cuxhaven
,
I. Matveev
1   HELIOS Seehospital Sahlenburg, Abt. Innere Medizin/Rheumatologie, Cuxhaven
,
I. Hartig
1   HELIOS Seehospital Sahlenburg, Abt. Innere Medizin/Rheumatologie, Cuxhaven
› Author Affiliations
Further Information

Publication History

Publication Date:
10 March 2018 (online)

Also available at
    Permissions and Reprints

Bei rheumatischen Beschwerden des Bewegungsapparates sollten Malignome als Ursasche paraneoplastischer Arthropathien immer bei den differenzialdiagnostischen Erwägungen berücksichtigt werden (1, 2). Rheumatische Symptome können als Erstmanifestation von Tumoren bestehen, diese ähneln den Beschwerden bei echten rheumatologischen Erkrankungen. Pathogenetisch sind diese Arthritiden Ausdruck eines direkten Gelenkbefalls oder einer paraneoplastischen Stimulation von autoimmunen Prozessen.

Nachdruck aus und zu zitieren als: arthritis + rheuma 2017; 37: 247–249

 

  • Literatur

  • 1 Naschitz JE, Rosner I. Musculoskeletal syndromes associated with malignancy (excluding hypertrophic osteoarthropathy). Curr Opin Rheumatol 2008; 20: 100-105.
    CrossrefPubMedGoogle Scholar
  • 2 Jardin F. Development of autoimmunity in lymphoma. Expert Rev Clin Immunol 2008; 04 (02) 247-266.
    CrossrefPubMedGoogle Scholar
  • 3 Van der Cruyssen B, Hoffman IE, Zmierczak H. et al. (2005) Anti-citrullinated peptide antibodies may occur in patients with psoriatic arthritis. Ann Rheum Dis 2005; 64: 1145-1149.
    CrossrefPubMedGoogle Scholar
  • 4 Mohammed K, Pope J, Le Riche N. et al. Association of severe inflammatory polyarthritis in primary Sjögren’s syndrome: clinical, serologic, and HLA analysis. J Rheumatol 2009; 36: 1937-1342.
    CrossrefPubMedGoogle Scholar
  • 5 Kakumanu P, Sobel ES, Narain S. et al. Citrulline dependence of anti-cyclic citrullinated peptide antibodies in systemic lupus erythematosus as a marker of deforming/erosive arthritis. J Rheumatol 2009; 36: 2682-2690.
    CrossrefPubMedGoogle Scholar
  • 6 Elkayam O, Segal R, Lidgi M. et al. Positive anti-cyclic citrullinated proteins and rheumatoid factor during active lung tuberculosis. Ann Rheum Dis 2006; 65: 1110-1112.
    CrossrefPubMedGoogle Scholar
  • 7 Kakumanu P, Yamagata H, Sobel ES. et al. Patients with pulmonary tuberculosis are frequently positive for anti-cyclic citrullinated peptide antibodies, but their sera also react with unmodified argininecontaining peptide. Arthritis Rheum 2008; 1576-1581.
    PubMedGoogle Scholar
  • 8 Shafaghi A, Mansour-Ghanaei F, Rostamnejad M. et al. Anti-cyclic citrullinated peptide antibodies in ulcerative colitis, and its relation with disease activity. Med J Islam Repub Iran 2014; 28: 76 [eCollection].
    PubMedGoogle Scholar
  • 9 Jardin F. Development of autoimmunity in lymphoma. Expert Rev Clin Immunol Mar 2008; 04 (02) 247-266.
    Google Scholar
  • 10 Morel J, Deschamps V, Toussirot E. et al. Characteristics and survival of 26 patients with paraneoplastic arthritis. Ann Rheum Dis 2008; 67: 244-247.
    CrossrefPubMedGoogle Scholar
  • 11 Naschitz JE, Rosner I. Musculoskeletal syndromes associated with malignancy (excluding hypertrophic osteoarthropathy). Curr Opin Rheumatol 2008; 20: 100-105.
    CrossrefPubMedGoogle Scholar
  • 12 Marinez-Levin M, Pineda C. Hypertrophic osteoarthropathy. In: Hochberg MC. et al. eds. Rheumatology. 3rd ed. Edinburgh: Mosby; 2003: 1763-1767.
    Google Scholar
  • 13 Dickinson CJ. The aetiology of clubbing and hypertrophic osteoarthropathy. Eur J Clin Invest 1993; 23: 330-338.
    CrossrefPubMedGoogle Scholar
  • 14 Hartig I, Matveeva I, Braun MG. Bei neu aufgetretenen Trommelschlegelfingern daran denken: Marie-Bamberger-Syndrom. Z Rheumatol 2015; 74 (08) 728-730.
    CrossrefPubMedGoogle Scholar
  • 15 Abe Y, Kurita S, Ohkubo Y. et al. A case of pulmonary adenocarcinoma associated with hypertrophic osteoarthropathy due to vascular endothelial growth factor. Anticancer Res 2002; 22: 3485-3488.
    Google Scholar
  • 16 Olan F, Portela M, Navarro C. et al. Circulating vascular endothelial growth factor concentrations in a case of pulmonary hypertrophic osteoarthropathy. Correlation with disease activity. J Rheumatol 2004; 31: 614-616.
    PubMedGoogle Scholar
  • 17 Mariette X, de Roquancourt A, d’Agay MF. et al. Monarthritis revealing non-Hodgkin’s T cell lymphoma of the synovium. Arthritis Rheum 1988; 31 (04) 571.
    CrossrefPubMedGoogle Scholar
  • 18 Ehrenfeld M, Gur H, Shoenfeld Y. Rheumatologic features of hematologic disease. Curr Opin Rheumatol 1999; 11: 62-67.
    CrossrefPubMedGoogle Scholar
  • 19 Caldwell DS. Musculoskeletal syndromes associated with malignancy. In: Kelley WN, Harris ED, Ruddy S, Sledge CB. Hrsg. Textbook of Rheumatology. Philadelphia: WB Saunders; 1997: 1521-1525.
    Google Scholar
  • 20 Kransdorf MJ. Malignant soft-tissue tumors in a large referral population: distribution of diagnoses by age, sex, and location. AJR Am J Roentgenol 1995; 164: 129-134.
    CrossrefPubMedGoogle Scholar
  • 21 Ehrenfeld M, Gur H, Shoenfeld Y. Rheumatologic features of hematologic disease. Curr Opin Rheumatol 1999; 11: 62-67.
    CrossrefPubMedGoogle Scholar